A novel fully automated MRI-based deep-learning method for classification of 1p/19q co-deletion status in brain gliomas

Background One of the most important recent discoveries in brain glioma biology has been the identification of the isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion status as markers for therapy and prognosis. 1p/19q co-deletion is the defining genomic marker for oligodendrogliomas and confers a better prognosis and treatment response than gliomas without it. Our group has previously developed a highly accurate deep-learning network for determining IDH mutation status using T2-weighted MRI only. The purpose of this study was to develop a similar 1p/19q deep-learning classification network. Methods Multi-parametric brain MRI and corresponding genomic information were obtained for 368 subjects from The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA). 1p/19 co-deletions were present in 130 subjects. 238 subjects were non co-deleted. A T2w image only network (1p/19q-net) was developed to perform 1p/19q co-deletion status classification and simultaneous single-label tumor segmentation using 3D-Dense-UNets. Threefold cross-validation was performed to generalize the network performance. ROC analysis was also performed. Dice-scores were computed to determine tumor segmentation accuracy. Results 1p/19q-net demonstrated a mean cross validation accuracy of 93.46% across the 3 folds (93.4%, 94.35%, and 92.62%, standard dev=0.8) in predicting 1p/19q co-deletion status with a sensitivity and specificity of 0.90 ±0.003 and 0.95 ±0.01, respectively and a mean AUC of 0.95 ±0.01. The whole tumor segmentation mean Dice-score was 0.80 ± 0.007. Conclusion We demonstrate high 1p/19q co-deletion classification accuracy using only T2-weighted MR images. This represents an important milestone toward using MRI to predict glioma histology, prognosis, and response to treatment. Keypoints 1. 1p/19 co-deletion status is an important genetic marker for gliomas. 2. We developed a non-invasive, MRI based, highly accurate deep-learning method for the determination of 1p/19q co-deletion status that only utilizes T2 weighted MR images IMPORTANCE OF THE STUDY One of the most important recent discoveries in brain glioma biology has been the identification of the isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion status as markers for therapy and prognosis. 1p/19q co-deletion is the defining genomic marker for oligodendrogliomas and confers a better prognosis and treatment response than gliomas without it. Currently, the only reliable way to determine 1p/19q mutation status requires analysis of glioma tissue obtained either via an invasive brain biopsy or following open surgical resection. The ability to non-invasively determine 1p/19q co-deletion status has significant implications in determining therapy and predicting prognosis. We developed a highly accurate, deep learning network that utilizes only T2-weighted MR images and outperforms previously published imagebased methods. The high classification accuracy of our T2w image only network (1p/19q-net) in predicting 1p/19q co-deletion status marks an important step towards image-based stratification of brain gliomas. Imminent clinical translation is feasible because T2-weighted MR imaging is widely available and routinely performed in the assessment of gliomas.

[1]  S. Klein,et al.  Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm , 2019, Clinical Cancer Research.

[2]  Ninon Burgos,et al.  New advances in the Clinica software platform for clinical neuroimaging studies , 2019 .

[3]  Karra A. Jones,et al.  Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status , 2017, Journal of Neuro-Oncology.

[4]  Arno Klein,et al.  Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements , 2014, NeuroImage.

[5]  Stephen M Smith,et al.  Fast robust automated brain extraction , 2002, Human brain mapping.

[6]  O. Topolcan,et al.  Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. , 2016, Anticancer research.

[7]  J. Hainfellner,et al.  FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice - a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). , 2011, Clinical neuropathology.

[8]  Mark W. Woolrich,et al.  Advances in functional and structural MR image analysis and implementation as FSL , 2004, NeuroImage.

[9]  M. Nikiforova,et al.  Molecular diagnostics of gliomas. , 2011, Archives of pathology & laboratory medicine.

[10]  Adelheid Woehrer,et al.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment. , 2015, CNS oncology.

[11]  K. Masamune,et al.  Prediction of lower-grade glioma molecular subtypes using deep learning , 2019, Journal of Neuro-Oncology.

[12]  Richard McKinley,et al.  Ensembles of Densely-Connected CNNs with Label-Uncertainty for Brain Tumor Segmentation , 2018, BrainLes@MICCAI.

[13]  A. Sapino,et al.  A “Weighted” Fluorescence In Situ Hybridization Strengthens the Favorable Prognostic Value of 1p/19q Codeletion in Pure and Mixed Oligodendroglial Tumors , 2013, Journal of neuropathology and experimental neurology.

[14]  Yoshua Bengio,et al.  The One Hundred Layers Tiramisu: Fully Convolutional DenseNets for Semantic Segmentation , 2016, 2017 IEEE Conference on Computer Vision and Pattern Recognition Workshops (CVPRW).

[15]  Jimmy Ba,et al.  Adam: A Method for Stochastic Optimization , 2014, ICLR.

[16]  Mark W. Woolrich,et al.  Bayesian analysis of neuroimaging data in FSL , 2009, NeuroImage.

[17]  Joachim M. Buhmann,et al.  Classification of brain MRI with big data and deep 3D convolutional neural networks , 2018, Medical Imaging.

[18]  Adolf Pfefferbaum,et al.  The SRI24 multichannel atlas of normal adult human brain structure , 2009, Human brain mapping.

[19]  Mark W. Woolrich,et al.  FSL , 2012, NeuroImage.

[20]  Jirí Sedlár,et al.  Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence , 2017, Journal of Digital Imaging.

[21]  Arno Klein,et al.  A reproducible evaluation of ANTs similarity metric performance in brain image registration , 2011, NeuroImage.

[22]  Sébastien Ourselin,et al.  Automatic Brain Tumor Segmentation Based on Cascaded Convolutional Neural Networks With Uncertainty Estimation , 2019, Front. Comput. Neurosci..

[23]  Stephen M. Moore,et al.  The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository , 2013, Journal of Digital Imaging.

[24]  Brian B. Avants,et al.  The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS) , 2015, IEEE Transactions on Medical Imaging.

[25]  Christos Davatzikos,et al.  Advancing The Cancer Genome Atlas glioma MRI collections with expert segmentation labels and radiomic features , 2017, Scientific Data.

[26]  Jie Yang,et al.  Deep Learning on MRI Affirms the Prominence of the Hippocampal Formation in Alzheimer’s Disease Classification , 2018, bioRxiv.

[27]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[28]  M. Mafra,et al.  Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation , 2019, BMC Cancer.

[29]  Yuan Yu,et al.  TensorFlow: A system for large-scale machine learning , 2016, OSDI.

[30]  J. Maldjian,et al.  A Novel Fully Automated Mri-Based Deep Learning Method for Classification of Idh Mutation Status in Brain Gliomas. , 2019, Neuro-oncology.

[31]  P. Baldi,et al.  Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas , 2018, American Journal of Neuroradiology.